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Abstract
Background: Successful embryo implantation depends on a well-timed maternal-embryonic crosstalk. Human chorionic
gonadotropin (hCG) secreted by the embryo is known to play a key role in this process and to trigger a complex signal
transduction cascade allowing the apposition, attachment, and invasion of the embryo into the decidualized
uterus. Production of hCG was reported to be dependent on blastocyst quality and several articles suggested
that intrauterine hCG injection increases pregnancy and implantation rates in IVF patients. However, no study
has as yet analysed birth rates as final outcome. Our objective was to determine whether clinical outcome after blastocyst
transfer can be improved by intrauterine injection of hCG and whether this is dependent on blastocyst quality.
Methods: A prospective randomised study was conducted in two settings. In cohort A, hCG application was performed
two days before blastocyst transfer. In cohort B, the administration of hCG occurred just prior to embryo transfer on day 5.
For both cohorts, patients were randomised to either intrauterine hCG application or to the control group that received
culture medium. Clinical outcome was analysed according to blastocyst quality of transferred embryos.
Results: The outcome of 182 IVF-cycles (cohort A) and 1004 IVF-cycles (cohort B) was analysed. All patients received a
fresh autologous blastocyst transfer on day five. Primary outcomes were pregnancy rates (PR), clinical pregnancy
rates (cPR), miscarriage rates (MR), and live birth rates (LBR). No improvement of clinical outcome after intrauterine hCG
administration on day 3 (cohort A) or day 5 (cohort B) was found, independently of blastocyst quality transferred. The
final outcome in cohort A: LBR after transfer of top blastocysts was 50.0 % with hCG and 53.3 % in the control group.
With non-top blastocysts, LBR of 17.1 % (hCG) and 18.2 % (control) were observed (n.s.). In cohort B, LBR with top
blastocysts was 53.3 % (hCG) and 48.4 % (control), with non-top blastocysts it came to 28.7 % (hCG) and 35.0 %
(control). The differences between the groups were statistically not significant. Furthermore, we investigated a possible
benefit of hCG administration in correlation with female age. In both age groups (<38 years and≥ 38 years) we found
similar LBR after treatment with hCG vs. medium. A LBR of 47.1 % vs. 48.7 % was obtained in the younger group and
26.6 % vs. 30.8 % in the older group.
Conclusions: In contrast to previous studies indicating a substantial benefit from intrauterine hCG application in
cleavage stage embryo transfers, in our study we could not find any evidence for improvement of clinical outcome in
blastocyst transfer cycles, neither with top nor with non-top quality morphology.
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Background
Successful implantation of the embryo depends on a complex
embryo-maternal crosstalk. In fact, human reproduction is
characterized by a high prevalence of pre-implantation em-
bryo loss of up to 75 % and a high frequency of clinical mis-
carriages, suggested to exceed a rate of 10 % of all clinical
pregnancies [1, 2]. Aside from euploidy and potential of
transferred embryo(s), the receptivity of the endometrium
is most crucial for successful implantation. Despite exten-
sive research, the embryo-maternal dialogue that orches-
trates the implantation process is still not fully understood.
Human chorionic gonadotropin (hCG) is a major player
in implantation, being involved in decidualization of the
endometrial stromal cells, trophoblast invasion, prolifera-
tion of uterine natural killer (uNK) cells, immunological
modulation at the maternal–foetal interface, stimulation
of endometrial angiogenesis, and maintenance of proges-
terone secretion by the corpus luteum [3–6]. It has been
assumed that hCG is responsible for a shift in gene ex-
pression in the uterine endometrium towards receptive-
ness for the implanting embryo [7].
It is well known that hCG is one of the earliest secreted
molecules in human cleavage stage embryos and is
later produced by the syncytiotrophoblast [8, 9]. The secre-
tion of hCG has been reported to be associated with poten-
tial as well as with morphology of the embryo. This is
consistent with the finding that embryos with poor mor-
phological grading display reduced ability to ‘attract’ endo-
metrial cells to prepare for implantation [10, 11]. In fact, a
recent prospective study indicates a supportive effect of
intrauterine hCG administration in transfers with poor
quality blastocysts [12].
In the early implantation period, hCG was shown to in-
hibit IGFBP-1, a member of the insulin-like growth factor-
binding protein family, that prevents the implantation
process by binding to α5β1-integrins on the cell-surface of
invading trophoblasts [13]. Further, hCG upregulates the
leukaemia inhibitory factor (LIF), vascular endothelial
growth factors (VEGFs) and matrix metalloproteinase-9
(MMP-9)- all factors known to be essential for embryo
attachment, placentation, trophoblast invasion, and a
multitude of other important processes in establishing
a pregnancy [13]. Several other in vitro and in vivo
studies in animal model systems but few in human
subjects indicate that hCG changes the paracrine milieu
of the endometrium [14–18].
Culture of embryos in in vitro fertilization (IVF)
involves an absence of intrauterine hCG signalling during
early embryo development (the first 3 to 5 days, depending
on the day of transfer). It was hypothesized that this cir-
cumstance could contribute to the relatively low implant-
ation rates in IVF, even after pre-implantation genetic
screening (PGS). Intrauterine supplementation of hCG
might circumvent this effect. Mansour and co-workers
were the first to investigate the impact of intrauterine hCG
injections on IVF-patients in a randomised trial. They
found that application of 500 IU hCG prior to cleavage
stage embryo transfer (ET) significantly improves preg-
nancy rates (PR) [19]. Similar results were reported in fur-
ther studies on cleavage stage ETs [12, 20–22]. However, in
blastocyst transfers, a beneficial effect of intrauterine hCG
administration could only be confirmed for low-quality
blastocysts [12].
The objective of this study was to investigate whether
the reported beneficial effect of intrauterine hCG admin-
istration on clinical outcome after IVF treatment can be
confirmed in blastocyst transfers, taking into account
the embryo quality. A single administration of hCG two
days before (cohort A) or shortly prior to ET was tested
(cohort B). In a large study population, pregnancy rate
(PR), clinical PR (cPR), and for the first time also miscar-
riage rate (MR) and live birth rate (LBR) were evaluated.
Methods
Study population and study design
This prospective observational study was approved by the
ethics committee of the Charles University in Prague,
EC-No. 355. All of the patients were counselled, and a
signed informed consent was obtained from all participants.
Our single-centre study included data on 182 IVF-cycles
with hCG administration two days prior to transfer of a
fresh blastocyst (cohort A) and 1004 cycles with hCG ad-
ministration on the day of ET (cohort B). Only single em-
bryo transfer (SET) or double embryo transfer (DET) were
performed, according to the medical history of patients (e.g.
caesarean section, risk for hyperstimulation syndrome) and
according to the patient’s decision. The primary objective
was to elucidate whether intrauterine hCG supplementa-
tion supports the implantation process in blastocyst trans-
fers. A secondary goal was to find out whether hCG has
detrimental effects such as an increased rate of biochemical
pregnancies or abortions after detection of the foetal heart-
beat. The reason for the application of hCG on either d3
(cohort A) or day 5 (cohort B) was that it has not yet been
elucidated what moment of administration will better
support endometrium receptivity in blastocyst transfers.
Patients were recruited between February 2013 and
February 2014 and randomised to either administration of
500 IU hCG (Pregnyl, ORGANON, Netherlands) dissolved
in 40 μl embryo culture medium G-2™ PLUS (Vitrolife,
Sweden) or administration of the same amount of culture
medium without hCG as control. Thereby, patients asking
for implantation supporting medium transfer on day three
were automatically allocated to cohort A. Counselling for
implantation supporting medium transfer was done after
one or two failed embryo transfers in the patient’s history.
On the day of ovum pick-up (OPU), randomisation in
both groups was done electronically with a random
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number generator using the Statistical Package for Social
Sciences (SPSS) software version 17.0 for Windows (SPSS
Inc., USA). Administration groups were patient blinded. In-
clusion criteria for both groups were fresh autologous
blastocyst transfer on day five and female age ≤ 43 years.
Exclusion criteria were oocyte donation cycles and patients
with reported recurrent implantation failure (≥3 negative
IVF-cycles). A flow chart diagram demonstrates the study
design, subject allocation, follow-up, and analysis (Fig. 1).
Ovarian stimulation and oocyte retrieval
For ovarian stimulation, the GnRHa long protocol was
applied [23]. The mean length of the stimulation period
was 11.6 days, and the mean stimulation dose was
2824 IU follicle-stimulating hormone (FSH). No statis-
tically significant differences in length and dose of
stimulating hormones between the groups were found.
The oocytes were retrieved 36 hours after intramuscular
administration of 5.000 IU hCG (Pregnyl, ORGANON,
Netherlands) (<0.2 % cycles) or 10.000 IU of hCG
(>99.8 % cycles).
Embryo culture
Based on the patients’ medical history, oocytes were fertil-
ized either by standard insemination (IVF: 1.2 %), or intra-
cytoplasmic morphologically selected injection (IMSI:
98.8 %) [24]. Embryo culture was performed in G-1™ PLUS
and G-2™ PLUS media (Vitrolife, Sweden) in four-well
dishes (Nunc A/S, Roskilde, Denmark). Medium was
renewed on day 3. On day 5, blastocyst quality was evalu-
ated, and the best or the best two blastocyst(s) in terms of
morphology were selected for transfer. Morphological grad-
ing was performed based on the degree of blastocoele ex-
pansion and the appearance of the inner cell mass as well
Fig. 1 Flow chart diagram of the study. Out of 1339 patients who underwent an IVF therapy, 1252 were found to be eligible to participate. Forty-three
patients declined to participate. Patients were randomized after oocyte retrieval in both cohorts. All patients underwent the same stimulation
protocol (GnRHa long)
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as the trophectoderm according to the classification of
Gardner and colleagues [25]. Blastocysts with a degree of
expansion of 2–5 and with A-grading for inner cell mass
and trophectoderm or a combination of A- and B-grading
were classified as top blastocysts. All other blastocysts were
grouped together as non-top blastocysts.
Cohort A: hCG administration on day 3
Administration of hCG in cohort A was done on day 3
after ovum pick-up (OPU) using an intrauterine insem-
ination cannula (Gynetics, Lommel, Belgium). Therefore,
40 μl of either hCG (500 IU) dissolved in embryo culture
medium or plain culture medium (control) were injected
in the intrauterine space 0.5 cm below the fundus.
Blastocyst transfer took place on day 5. Mean female age
was 35.8 years (range 22–43 years), No statistically sig-
nificant differences in patients’ characteristics [female
age, body mass index (BMI), number of MII oocytes per
OPU, type as well as cause of infertility, and percentage
of IMSI and IVF] in the groups allocated to hCG or in
the control group were found (Table 1).
Cohort B: hCG administration on day 5
Human chorionic gonadotropin was administered 3 mi-
nutes prior to blastocyst transfer on day 5 in cohort B.
Therefore, either 40 μl hCG dissolved in embryo culture
medium or 40 μl plain culture medium was applied to
the surface of the endometrium using a Wallace embryo
replacement catheter (Smiths Medical Inaternation,
Kent, UK) 0.5 cm below the uterine fundus. Transfer of
blastocysts was performed as described previously [26]. No
statistically significant differences in patient characteristics
between hCG and control groups were observed (Table 2).
Outcome measures
Fourteen days after blastocyst transfer, urinary ß-hCG
was tested to determine the pregnancy rate (PR). Clinical
pregnancy rate (cPR) was confirmed by at least one
foetal heartbeat observed by ultrasound 8 to 12 weeks
after transfer. The implantation rate (IR) was calculated
by number of foetal heartbeats per transferred blasto-
cyst. LBR is the number of deliveries per blastocyst
transfer. Miscarriage was defined as pregnancy loss after
detection of positive heartbeat by ultrasound in gestation
week 8 to 12
Statistical analysis
Primary study outcomes were IR, PR, cPR, and LBR. All
rates were compared by a chi-square distribution and by
calculating 95 % confidence intervals of the relative risk
and risk difference. An alpha error of less than 0.05 was
considered statistically significant. Power analysis was
performed, revealing that 376 patients in each cohort
are needed to detect a 10 % difference in birth rate with
80 % power and a single-tailed alpha of 0.05. Differences
in means of numerical data were tested by one-way
Table 1 Patients’ characteristics of cohort A: hCG administration
on day three
Characteristics hCG (n = 89) culture medium
(n = 93)
P-Value




35.5 ± 5.0 (25–43) 0.365
BMI (kg/m2) mean ± s.d. 23.0 ± 3.0 23.6 ± 4.2 0.383
No. MII oocytes/ OPU
mean ± s.d.
9.2 ± 5.0 9.0 ± 5.2 0.796
Type of Infertility (%)
- Primary Infertility 50 (56.2 %) 42 (45.2 %) 0.137
- Secondary Infertility 39 (43.8 %) 51 (54.8 %)
Cause of Infertility (%)
- Female factor 19 (21.4 %) 29 (31.3 %) 0.168
- Male factor 38 (42.3 %) 27 (29.0 %)
- Mixed 25 (28.1 %) 32 (34.4 %)
- Idiopathic 7 (7.9 %) 5 (5.4 %)
Ranges or percentages respectively are given in brackets, MII oocytes: Metaphase II
oocytes; OPU= ovum pick-up; s.d.: standard deviation
Baseline characteristics of IVF patients receiving either 40 μl of hCG (500 IU)
dissolved in embryo culture medium or plain culture medium (control group)
2 days before transfer. Primary infertility was defined as the inability to become
pregnant or the inability to carry a pregnancy to a live birth. Secondary infertility
was defined as the inability to become pregnant or the inability to carry a
pregnancy to a live birth following either a previous pregnancy or a previous ability
to carry a pregnancy to a live birth








mean ± s.d (range)
37.1 ± 4.0 (20–43) 36.7 ± 4.3 (21–43) 0.102
BMI (kg/m2)mean ± s.d 22.9 ± 4.4 22.9 ± 4.3 0.917
No. MII oocytes/
OPUmean ± s.d
8.7 ± 5.0 9.3 ± 5.6 0.083
Type of Infertility (%)
- Primary Infertility 249 (48.8 %) 236 (47.8 %) 0.752
- Secondary Infertility 261 (51.2 %) 258 (52.2 %)
Cause of Infertility (%)
- Female factor 77 (15.1 %) 63 (12.8 %) 0.451
- Male factor 220 (43.1 %) 229 (46.4 %)
- Mixed 115 (22.5 %) 119 (24.1 %)
- Idiopathic 98 (19.2 %) 83 (16.8 %)
Ranges or percentages respectively are given in brackets, MII oocytes:
Metaphase II oocytes; OPU = ovum pick-up; s.d.: standard deviation
Baseline characteristics of IVF patients receiving either 40 μl hCG dissolved in
embryo culture medium or 40 μl plain culture (control) on day 5 after oocyte
retrieval 3 minutes prior to transfer. Primary infertility was defined as the
inability to become pregnant or the inability to carry a pregnancy to a live
birth. Secondary infertility was defined as the inability to become pregnant or
the inability to carry a pregnancy to a live birth following either a previous
pregnancy or a previous ability to carry a pregnancy to a live birth
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Anova using the F distribution. Statistical analysis was
performed using the Statistical Package for Social Sci-
ences (SPSS) software version 17.0 for Windows (SPSS
Inc., USA).
Results
Cohort A: hCG administration on day 3
Groups were subdivided according to the blastocyst
quality of transferred embryos. Ninety-seven women had
transfers with top blastocysts. Forty-eight patients were
randomised to the hCG group, whereas the control
group of 49 patients had an uterine injection of embryo
culture medium 2 days prior to transfer (Table 3). No
statistically significant differences in female age or num-
ber of embryos transferred were found between the
groups. In the follow-up, no difference in PR (60.4 % vs.
65.3 %, respectively), cPR (52.1 % vs. 57.1 %, respect-
ively), LBR (50.0 % vs. 53.1 %, respectively), or MR
(2.1 % vs. 4.1 %, respectively) was observed after admin-
istration of intrauterine hCG vs. medium.
In patients receiving transfers of non-top blastocysts, 41
women were allocated to the hCG injection prior to trans-
fer and 44 women to injection with medium (control
group). Female age, endometrium build-up, and number of
transferred embryos were comparable in both groups
(Table 3). No statistically significant differences in PR
(31.7 % vs. 29.5 %, respectively), cPR (19.5 % vs. 20.5 %, re-
spectively), LBR (17.1 % vs. 18.2 %, respectively), and MR
(2.4 % vs. 2.3 %, respectively) were found after intrauterine
hCG vs. medium injection.
The twin birth rate after transfer of top blastocysts
was 12.5 % (hCG) vs. 15.4 % (control), with transfer of
non-top blastocysts 28.6 % (hCG) vs. 12.5 % (control).
The differences were not statistically significant.
Cohort B: hCG administration on day 5
Impact of hCG application in relation to blastocyst quality
A total of 357 patients in this cohort received a transfer
with top blastocyst(s), 169 of which were allocated to
intrauterine hCG injection and 188 to injection with
medium (Table 4). Female age (mean 36.1 vs. 35.7 years)
and number of embryos transferred (mean 1.6 in each
group) were comparable between groups. No statistically
significant differences in clinical outcome were observed
(PR: 67.5 % vs. 59.6 %, respectively; cPR: 59.2 % vs.
54.8 %, respectively; LBR: 53.3 % vs. 48.4 %, respectively,
and MR: 5.9 % vs. 6.4 %, respectively) after treatment
with hCG vs. medium.
Furthermore, 647 patients had a transfer with non-top
blastocyst(s), whereas 341 received an intrauterine injec-
tion with hCG prior to transfer and 306 received an
injection with medium. A mean number of 1.7 vs. 1.8
embryos was transferred. No statistically significant dif-
ferences were observed in PR (43.1 % vs. 48.7 %, respect-
ively), LBR (28.7 % vs. 35.0 %, respectively), and MR
(4.4 % vs. 5.9 %, respectively) after injection with hCG
vs. medium. However, cPR (33.1 % vs. 40.8 %, respect-
ively) as well as IR (21.9 % vs. 27.1 %, respectively) were
significantly higher in the controls (Table 4).
In cohort B, the twin birth rate after top blastocyst
transfer was 10.0 % (hCG) vs. 11.0 % (control), and
6.1 % (hCG) vs. 8.4 % (control), respectively with the
same number of embryos transferred in the groups
(Table 2). No statistically significant difference between
the groups was found.
Benefit of hCG application in relation to female age
On the same data-set we investigated a possible correlation
between age and hCG administration. Two age-groups
were defined: women <38 years (482 ETs) and ≥ 38 years
Table 3 Clinical outcome in cohort A: hCG administration on day 3
Transfer with top blastocysts Transfer with non-top blastocysts
Characteristics hCG (n = 48) culture medium
(n = 49)
P-Value hCG (n = 41) culture medium
(n = 44)
P-Value
Female age (years) mean ± s.d. (range) 35.3 ± 4.2 (22–42) 34.9 ± 5.0 (25–42) 0.641 37.0 ± 3.9 (30–43) 36.1 ± 5.0 (25–43) 0.380
Endometrium height (mm) mean ± s.d. 11.0 ± 2.6 10.8 ± 2.4 0.817 11.6 ± 2.2 10.8 ± 1.9 0.110
No. Embryos transferred Embryos / ET mean ± s.d. 75 1.6 ± 0.5 76 1.6 ± 0.5 0.911 69 1.7 ± 0.5 77 1.8 ± 0.5 0.522
Proportion of difficult ETs 10.4 % 8.2 % 0.702 12.2 % 9.1 % 0.642
No. Pregnancies (PR) 29 (60.4 %) 32 (65.3 %) 0.618 13 (31.7 %) 13 (29.5 %) 0.829
No. Clinical pregnancies (cPR) 25 (52.1 %) 28 (57.1 %) 0.617 8 (19.5 %) 9 (20.5 %) 0.914
No. Implanted embryos (IR) 30 (40.0 %) 32 (42.1 %) 0.793 11 (15.9 %) 12 (15.6 %) 0.953
No. Births (LBR) 24 (50.0 %) 26 (53.1 %) 0.763 7 (17.1 %) 8 (18.2 %) 0.893
No. Babies born 27 30 9 9
No. Miscarriages (MR) 1 (2.1 %) 2 (4.1 %) 0.570 1 (2.4 %) 1 (2.3 %) 0.960
Ranges or percentages respectively are given in brackets, s.d.: standard deviation
IVF characteristics and clinical outcome of cohort A. Miscarriage rate was defined as pregnancy loss after the detection of foetal heartbeat
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(522 ETs). In the younger group, after treatment with hCG
vs. medium, we found similar PR (60.4 % vs. 60.2 %, re-
spectively) and LBR (47.1 % vs. 48.7 %, respectively). In
women ≥ 38 years PR amounted to 41.4 % (hCG) vs. 44.1 %
(control), and LBR 26.6 % (hCG) vs. 30.8 % (control), re-
spectively. Quality of blastocysts transferred was similar in
the groups and clinical outcome statistically not significant
(data not shown).
Discussion
In our study we investigated the impact of intrauterine
hCG administration prior transfer in relation to blasto-
cyst morphology in a large study population that includes
birth outcome as primary outcome. In contrast to previous
findings after cleavage stage embryo transfers, but in ac-
cordance with studies on blastocyst transfers, the present
study did not show that intrauterine hCG application
provides additional benefit in various settings [27]. In
fact, neither intrauterine hCG injection on day three
nor on day five had a beneficial effect on PR, DR, or IR.
This was true in transfers with top blastocysts as well
as in those with non-top blastocysts.
Several studies postulate that hCG is a key-player in the
implantation process [8, 9, 14–18]. As one of the first sig-
nalling molecules, hCG is already secreted by cleavage stage
embryos. In blastocysts, hCG is then exclusively produced
by the trophectoderm (TE) cells. Human chorionic gonado-
tropin isoforms and the released amount of hCG were
found to be related to the developmental stage, but also to
the morphological quality of the blastocyst and to the TE
grading in particular [10, 28–31]. In line with these find-
ings, TE quality was suggested to be the most important
predictor for implantation [32–34]. It has recently been as-
sumed that decidual cells select against embryos lacking fit-
ness including those with insufficient hCG production [35].
Thus, our study aimed to investigate a possible positive
effect of intrauterine hCG injection on implantation and
clinical outcome in blastocyst transfers with regard to
blastocyst morphology.
Our finding, that hCG did not improve clinical out-
come neither in top-blastocyst transfers nor in non-top
blastocyst transfer is in contradiction to some previous
papers reporting positive results from cleavage stage em-
bryo transfers (Table 5). Mansour and co-workers found
in a randomised trial including 212 cycles that applica-
tion of 500 IU hCG prior to transfer of cleavage stage
embryos significantly improves pregnancy rates [19]. In
a similar approach, Zarei and colleagues reported an in-
crease in PR by intrauterine injection of 250 μg recom-
binant hCG (equivalent to 6,500 IU) prior to transfer on
day three [20]. In both studies, the age of patients was
substantially lower compared with our cohorts (Table 5).
Advanced female age is the most limiting factor for IVF
success. As some of the studies that have found a benefi-
cial effect of hCG administration were done on younger
patients, we investigated a possible benefit of hCG ad-
ministration on patients with advanced maternal age.
However, no benefit of hCG administration was found
for different age groups 20 to 38 years or 38 to 43 years.
In line with our previous suggestion, that a beneficial
effect of hCG application is dependent on the stage of
the embryo(s) transferred, a recent study investigated
blastocyst transfers in women >35 years [12]. No in-
crease in cPR was observed in the hCG group. However,
authors reported after further sub-grouping according to
blastocyst quality, a higher PR with hCG injection when
poor quality blastocysts were transferred [12]. This find-
ing could not be observed in our study, which could be
explained by the fact that in the cited study, the number
of patients per group was substantially low. Our obser-
vations suggest that a putative decreased production of
implantation supporting mediators in embryos with poor
Table 4 Clinical outcome in cohort B: hCG administration on day 5
Transfer with top blastocysts Transfer with non-top blastocysts
Characteristics hCG (n = 169) culture medium
(n = 188)
P-Value hCG (n = 341) culture medium
(n = 306)
P-Value
Female age (years) mean ± s.d. (range) 36.1 ± 4.0 (22–43) 35.7 ± 4.3 (20–43) 0.331 37.6 ± 3.9 (27–43) 37.3 ± 4.2 (25–43) 0.330
Endometrium height (mm) mean ± s.d. 10.2 ± 1.5 9.9 ± 1.6 0.102 9.8 ± 1.7 9.7 ± 1.6 0.619
No. Embryos transferred Embryos / ET mean ± s.d. 274 1.6 ± 0.5 302 1.6 ± 0.5 0.781 594 1.7 ± 0.5 547 1.8 ± 0.4 0.208
Proportion of difficult ETs 10.7 % 9.0 % 0.610 10.6 % 10.8 % 0.926
No. Pregnancies (PR) 114 (67.5 %) 112 (59.6 %) 0.123 147 (43.1 %) 149 (48.7 %) 0.155
No. Clinical pregnancies (cPR) 100 (59.2 %) 103 (54.8 %) 0.404 113 (33.1 %) 125 (40.8 %) 0.042
No. Implanted embryos (IR) 123 (44.9 %) 128 (42.4 %) 0.545 130 (21.9 %) 148 (27.1 %) 0.042
No. Births (LBR) 90 (53.3 %) 91 (48.4 %) 0.360 98 (28.7 %) 107 (35.0 %) 0.089
No. Babies born 108 112 110 126
No. Miscarriages (MR) 10 (5.9 %) 12 (6.4 %) 0.855 15 (4.4 %) 18 (5.9 %) 0.392
Numbers or percentages respectively are given in brackets, s.d.: standard deviation
IVF characteristics and clinical outcome of cohort B. Miscarriage rate was defined as pregnancy loss after the detection of foetal heartbeat
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Table 5 Overview of recent studies on intrauterine hCG infusion










et al., 2011 [19]
212 ETs in first IVF/
ICSI cycle (male factor)
Control:
28.3a hCG: 28.4a
Fresh Day 2 or 3 500 IU purified urinary hCG
(IBSA) 7 min prior ET
Control: 29.5 % hCG:
41.6 %
Control: 60 % hCG: 75 %
Rebolloso
et al., 2013 [22]
121 ETs IVF/ICSI cycles
(38 in hCG group)
n.d. n.d. Day 3 (n = 79)
Day 5 (n = 42)
500 IU urinary hCG (n.d.)
7 min before ET
Control: 17.5 % hCG:
17.7 %
Control: 26.3 % hCG: 26.5 %
Zarei et al.,
2014 [20]




Fresh Day 3 250 μg rhCG (Ovitrelle)
(equivalent to 6,500 IU)
12 min prior ET
Control: 22.4 % hCG:
36.9 %
Control 18.4 % hCG: 32.1 %
Santibañez
et al., 2014 [21]







500 IU purified urinary hCG
(Choragon) 4 min prior ET
Control: 33.0 % hCG: 50.4 %
Riboldi et al.,
2013 [12]
99 ETs in women





500 IU rhCG (n.d.) 6 hours
prior ET
Control: 36.1 % hCG 39.3 %
Hong et al.,
2014 [27]






500 IU urinary hCG (Novarel) 3 min
prior ET
Control: 48.1 % hCG:
44.2 %
Control: 58.8 % hCG: 52.0 %
Our results 182 ETs in women
≤43a without RIF
Control: 35.5a
hCG: 36.1a All: 35.8a
Fresh Day 5 500 IU urinary hCG (Pregnyl)
2 days prior ET
Top Blastocysts Control:





57.1 % hCG: 52.1 % Non-top
Blastocysts Control: 20.5 %
hCG: 19.5 %
Top Blastocysts Control:
53.1 % hCG: 50.0 % Non-
top Blastocysts Control:
18.2 % hCG: 17.1 %




Fresh Day 5 500 IU urinary hCG (Pregnyl)
3 min prior ET
Top Blastocysts Control:
42.4 % hCG: 44.9 %
Non-top Blastocysts
Control: 27.1 % hCG:
21.9 %
Top Blastocysts Control:
54.8 % hCG: 59.2 % Non-top
Blastocysts Control: 40.8 %
hCG: 33.1 %
Top Blastocysts Control:
48.4 % hCG 53.3 % Non-
top Blastocysts Control:
35.0 % hCG: 28.7 %
a: years; cPR: clinical pregnancy rate; IR: implantation rate; LBR: live birth rate; n.d.: not defined; RIF: recurrent implantation failure













morphology cannot be overcome by intrauterine admin-
istration of hCG. On the contrary, a statistically signifi-
cant negative effect of hCG administration prior to
transfer on cPR and IR was observed in the poor morph-
ology group. This might support the hypothesis that a
well coordinated signalling is most crucial for a proper
implantation and the enhancing of one signal might
even worsen the situation. Thus, more trials addressing
this issue might be needed. However, LBR was not statis-
tically lower with hCG application (Table 4).
Moreover, in line with our results, the study of Rebol-
loso and colleagues did not observe any improvement in
clinical outcome after administration of hCG [22]. This
randomised study performed on a small cohort, includ-
ing 38 patients who received 500 IU hCG and 83 pa-
tients in the control group. Transfers included both
cleavage stage and blastocyst transfers. Interestingly, the
authors reported a statistically significantly higher twin
pregnancy rate after hCG injection (66 % vs. 8.3 % in
hCG vs. control). This finding could not be confirmed in
our data set. No differences in the two study cohorts
were observed.
Consistent with our study, a recently published paper
reported no impact of intrauterine hCG injection prior
to blastocyst transfer [27]. This investigation included
300 fresh or frozen transfers. No statistically significant
differences in IR or cPR between the hCG and control
groups were observed. This was also true for a subgroup
of patients receiving a transfer after comprehensive
chromosome screening. These findings confirm our re-
sults, however, the cited study was discontinued before
completion of the calculated sample size. Most import-
ant, the quality of blastocysts transferred was not further
investigated, although it is well accepted that besides fe-
male age and the cause of infertility, blastocyst morph-
ology is one of the most important parameters that
determines whether or not implantation is successful
[25, 36]. Data analysis in respect to the quality of trans-
ferred blastocysts is crucial, as embryo quality is prob-
ably an indicator of both: the hCG production and the
probability of implantation [10, 11]. Our study clearly
demonstrates that neither an intrauterine injection of
hCG two days prior to ET nor an injection on the day of
blastocyst transfer can overcome the reported reduced
implantation chances of a poor quality blastocyst. This
suggestion is in line with previous publication of Eftekhar
et al. [37] and Ben-Meir et al. [38]. Both research groups
observed that the subcutaneous administration of recom-
binant hCG in frozen-thawed ETcycles on the day of trans-
fer does not have any advantages in terms of pregnancy
and implantation rates. Further, in line with several previ-
ous reports, we did not observe an increase in miscarriages
in the hCG groups when compared to controls. These re-
sults confirm previous findings [19–22, 27]. In conclusion,
this large prospective randomised study could not find any
beneficial effect of intrauterine hCG injection (500 IU) in
blastocyst transfers. This was true for top as well as for
non-top blastocyst. The strengths of the present study are
that it is an RCT with a high number of analysed subjects
in two different set-ups, a unique stimulation scheme and
the evaluation of the outcome in correlation to embryo
quality. However, it has to be mentioned that the patient
cohort receiving hCG injection on day 3 in our study was
substantially smaller as compared to cohort B receiving
hCG on day 5 prior to transfer and therefore this group did
not reach the calculated power analysis. The main limita-
tion is the restriction to fresh blastocyst transfers. The
WOI is assumed to be altered by high dosages of exogen-
ous hCG (as it is done during cycles of COH) [39]. Thus, a
beneficial effect of intrauterine hCG administration in cryo-
cycles cannot be excluded as the transfer of vitrified/thawed
blastocysts is often suggested to be more physiologic.
Furthermore, our results apply only to the patients clientele
investigated in this study (autologous IVF cycles in pa-
tients ≤ 43 years). Additionally, as source and brand were
found to be crucial for the mode of hCG action [18], we
cannot exclude that other hCG concentrations or other
hCG preparations might have different impacts.
Conclusions
The high number of IVF cycles with failed implantation
despite the transfer of apparently good and viable embryos
with respect to their morphology has led to the adoption of
adjuvant therapies with the aim to improve endometrial re-
ceptivity and implantation rates. However, one must keep
in mind that the molecular background of the implantation
process remains a complex issue, and intervention therapies
are not as simple as has often been suggested. Further stud-
ies are crucial for a better understanding of the molecular
mechanisms of embryonic-maternal cross-talk, taking into
consideration the possible differences in hCG molecules
such as embryonic vs. endometrial vs. recombinant hCG,
and to implement truly effective and innovative therapies in
assisted reproduction.
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